Aprinoia Therapeutics (Aprinoia Therapeutics) Net Cash per Share : $-3.19 (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Aprinoia Therapeutics's Net Cash per Share for the quarter that ended in Jun. 2023 was $-3.19.

The historical rank and industry rank for Aprinoia Therapeutics's Net Cash per Share or its related term are showing as below:

APRI's Price-to-Net-Cash is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.92
* Ranked among companies with meaningful Price-to-Net-Cash only.

Aprinoia Therapeutics Net Cash per Share Historical Data

The historical data trend for Aprinoia Therapeutics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Net Cash per Share Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Net Cash per Share

-1.86

-2.87

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Net Cash per Share	-1.86	-	-2.87	-3.19

Competitive Comparison of Aprinoia Therapeutics's Net Cash per Share

For the Biotechnology subindustry, Aprinoia Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Price-to-Net-Cash falls into.

Aprinoia Therapeutics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Aprinoia Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

	Net Cash per Share (A: Dec. 2022 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1.221	-	81.093	-	0)	/	27.829
=	-2.87

Aprinoia Therapeutics's Net Cash per Share for the quarter that ended in Jun. 2023 is calculated as

	Net Cash per Share (Q: Jun. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(7.731	-	96.408	-	0)	/	27.829
=	-3.19

Aprinoia Therapeutics (NAS:APRI) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Aprinoia Therapeutics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines